IgA Nephropathy
Advertisement
A systematic evaluation compared the incidence of IgAN and changes in its pathology before and during the COVID-19 pandemic.
Researchers wanted to understand kidney changes with O. felineus infection and whether there is an association with IgAN.
A teen who presented with nephrotic syndrome was diagnosed with both dense deposit disease and IgA nephropathy.
Researchers reported the progression of kidney function throughout the course of IgA nephropathy.
Are immunosuppressive therapies used to treat glomerular disease are related to higher cardiovascular risks?
Interim APPLAUSE-IgAN data showed that iptacopan was superior to placebo at reducing proteinuria at nine months.
A MAMS platform trial will examine use of antiproteinuric and immunomodulatory therapies in glomerular diseases.
Zigakibart for treatment of IgA nephropathy (IgAN) was well tolerated, reduced proteinuria, and stabilized eGFR at 76 weeks.
Researchers reported data from APPLAUSE-IgAN assessing the effects of iptacopan on proteinuria at nine months.
A study examined the clinical relevance of urinary mRNA levels in patients with IgA nephropathy (IgAN).
A study examined whether COVID-19 independently affects the subsequent trajectory of kidney function in patients with IgAN.
A study analyzed the fecal microbiome of patients with IgA nephropathy, focusing on their immune response to microbiota.
Researchers examined the role of urinary sodium excretion and the progression of immunoglobulin A nephropathy (IgAN).
Vlado Perkovic spoke about findings from the FLOW, APPLAUSE-IgAN, and CREDENCE trials presented at ASN Kidney Week.
A study examined a possible link between IgA nephropathy (IgAN) and inflammatory skin diseases.
Could adding serum C3 and C4 levels to existing predictive models for IgA nephropathy (IgAN) improve their accuracy?
Could the systemic inflammatory response index (SIRI) be a useful measure of renal prognosis in IgA nephropathy (IgAN)?
Diffuse magnetic imaging resonance shows promise for evaluating clinical and pathological changes in patients with IgAN.
Purespring Therapeutics received $105M in Series B funding to develop gene therapies for kidney diseases, including IgAN.
Long-term results of a study of atacicept to treat IgA nephropathy (IgAN) will be presented at ASN Kidney Week.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.